Arrowhead Pharmaceuticals Kicks Off 2026 Summer R&D Webinar Series with Cardiometabolic Focus
Event summary
- Arrowhead Pharmaceuticals to host first webinar in its 2026 Summer Series of R&D webinars on June 29, 2026, focusing on its cardiometabolic pipeline.
- Webinar to feature presentations from Arrowhead management and Steven Nissen, M.D., Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic.
- Agenda includes overviews of Arrowhead’s cardiometabolic pipeline, technology, and specific clinical candidates: Plozasiran (APOC3), Zodasiran (ANGPTL3), and ARO-DIMER-PA (PCSK9/APOC3).
- Each webinar in the series will be approximately 60-90 minutes in duration with live webcasts and replays available on Arrowhead’s website.
The big picture
Arrowhead Pharmaceuticals’ 2026 Summer Series of R&D webinars underscores its strategic focus on advancing its RNAi-based therapeutics. The cardiometabolic pipeline, highlighted in the first webinar, is critical as the company seeks to differentiate itself in a competitive landscape. The involvement of key opinion leaders like Steven Nissen from the Cleveland Clinic adds weight to Arrowhead’s efforts to validate its clinical candidates and treatment landscapes.
What we're watching
- Pipeline Progress
- How Arrowhead’s cardiometabolic pipeline advances will position it against competitors in the RNA interference space.
- Key Opinion Leader
- Whether Steven Nissen’s involvement will lend credibility and accelerate adoption of Arrowhead’s cardiometabolic therapies.
- Market Reception
- The pace at which Arrowhead can translate webinar insights into tangible clinical and commercial milestones.
Related topics